David Millan
Chief Scientific Officer Auron Therapeutics
Seminars
Tuesday 28th October 2025
Advancing AUTX-703 as a First-in-Class, Potent, Selective & Orally Bioavailable Degrader of the Epigenetic Regulator KAT2A/B
3:00 pm
